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A holistic view of the complex
Recent studies on gene regulation in Saccharomyces cerevisiae support
the view that eukaryotic activators stimulate transcription by recruiting
an RNA polymerase I.holoenzyme to the promoter in a single step.
A textbook combination of biochemistry and genetics
has suggested a new model for gene activation in the
yeast Saccharomyces cerevisiae. The model is based on the
premise that the transcriptional apparatus in yeast exists
in the form of a holoenzyme containing both RNA
polymerase II and ancillary factors, which endow it with
the capacity to recognize promoter DNA and respond to
upstream activators. In this scheme, an activator would
stimulate transcription by contacting a surface of the
holoenzyme and recruiting it to DNA in a single step -
a mechanism conceptually similar to gene activation in
prokaryotic cells. The holoenzyme model arose from
two observations: the biochemical isolation of a largely
preassembled transcription complex from yeast extracts
[1,2] and experiments in vivo, which indicated that teth-
ering diverse components of the yeast transcriptional
machinery to DNA could circumvent the requirement
for upstream activators [3-5].
Although the concept of a holoenzyme originated from
studies of the bacterium Escherichia coli over two decades
ago, its existence in eukaryotic cells was unexpected. The
traditional view of eukaryotic gene activation proposed
that activators stimulate the stepwise assembly of a multi-
component transcription complex, comprising RNA
polymerase II and six general factors called TFIIA,
TFIIB, TFIID, TFIIE, TFIIF and TFIIH, which are con-
served between yeast and humans [6]. The assembly of
the complex was thought to be nucleated by the binding
of TFIID to the TATA box, and to culminate in the
binding of TFIIH. This notion predominated until
independent discoveries by the laboratories of Roger
Kornberg and Rick Young of a form of RNA poly-
merase II that was associated with proteins not consid-
ered part of the core enzyme [1,2]. Both laboratories
referred to these macromolecular assemblies as holo-
enzymes, although the term is not strictly correct by
comparison to the prokaryotic prototype.
The holoenzyme isolated by Young and co-workers
emerged from a genetic analysis of the carboxy-terminal
domain of the largest RNA polymerase II subunit
(reviewed in [7]). This domain contains 26 heptapeptide
repeats, the phosphorylation of which by cyclin-depen-
dent kinases apparently plays a role in transcriptional
control. Deletion of all but 10-12 of these repeats con-
fers a cold-sensitive phenotype on yeast. Genetic sup-
pressors of the conditional lethal phenotype, termed
suppressors of RNA polymerase B (II) or SRBs, restore
the ability of the yeast to grow in the cold. Although the
precise physiological functions of the SRB proteins are
not fully understood, biochemical analysis reveals that
they are associated with a complex containing stoichio-
metric amounts of RNA polymerase II and the yeast
general transcription factors TFIIB, TFIIH and TFIIF
[2]. This complex can support both basal and activator-
responsive transcription in vitro upon addition of only
TFIIE and the TATA-box-binding protein (TBP), a sub-
unit of TFIID. Kornberg and colleagues isolated a smaller
version of the holoenzyme, comprising RNA poly-
merase II and a complex of proteins termed the mediator
[1]. Analysis of the mediator showed it to be composed
of the SRBs, TFIIF and two co-activators called SUG1
and GAL11, later found to be components of the
holoenzyme isolated by Young.
The observation by Young and colleagues that only a
fraction of the cellular RNA polymerase II and general
transcription factors is present in the holoenzyme initially
raised doubts about its authenticity. However, because
almost all of the SRBs are associated, the finding that a
temperature-sensitive SRB4 mutant leads to a complete
shut-off of mRNA synthesis at the restrictive tempera-
ture [8] provided a compelling argument that the
holoenzyme is the transcriptionally active form of RNA
polymerase in vivo. Such a discovery has broad implica-
tions for the mechanism of eukaryotic gene activation,
perhaps best considered by using the E. coli holoenzyme
as a model (Fig. la,b).
The E. coli RNA polymerase holoenzyme consists of a
four-subunit core (a2 13') complexed with a r subunit.
Promoter recognition is conferred by the carboxyl ter-
minus of the a subunit, which in some promoters binds
the 'UP' element at position -50 [9], and a r factor,
often 70 , which binds the conserved -35 and -10
regions. Prokaryotic activators stimulate transcription in
a single step by contacting either the a subunit, in the
case of the catabolite activator protein (CAP) [10], or the
r subunit, in the case of the bacteriophage X cI protein
[11]. These interactions have been shown to enhance
transcription by increased recruitment of the holo-
enzyme to the promoter, or isomerization from the
closed to the open complex. Within an artificial pro-
moter context, CAP and cI evidently bind the holoen-
zyme simultaneously, generating a greater-than-additive
or synergistic transcriptional response [12].
The eukaryotic holoenzyme, unlike its prokaryotic coun-
terpart, lacks promoter-recognition capabilities in vitro.
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Fig. 1. (a,b) A conserved mechanism of
gene activation. Activators (Act) func-
tion by contacting components of the
holoenzymes in E. coli and yeast. (a) In
E. coil, putative activator targets include
the a and subunits. (b) In yeast, puta-
tive targets include TBP, the mediator,
general transcription factors such as
TFIIB and TFIIH, and TAFs. The func-
tional consequences of all these interac-
tions would be the same - recruitment
of the holoenzyme and/or isomerization
from an inactive to an active form. (c)
The requirement for activators can be
bypassed by fusing different compo-
nents of the holoenzyme to a DNA-
binding domain such as that of LexA.
However, two results are consistent with the idea that
TBP may be a component of the holoenzyme in vivo.
These studies also provided support for the notion that
activators recruit the holoenzyme to the promoter in a
single step. The first result, from an experiment carried
out independently by the laboratories of Struhl, Strubin
and Lis, showed that fusing TBP to high-affinity, tran-
scriptionally inactive DNA-binding domains, including
those of LexA [5], RFX [4] or GAL4 (J. Lis, personal
communication), resulted in high levels of transcription in
vivo from reporter templates bearing upstream binding
sites for these proteins (Fig. 1c). The efficiency of the
stimulation varied such that in some cases the require-
ment for an activator was effectively bypassed, and in
other cases upstream activators such as GAL4-VP16 stim-
ulated significantly more transcription than the TBP-
fusion proteins, implying additional roles for the activator.
The observation that TBP mutants unable to bind DNA
did not support transcription suggested that binding to
the TATA box was required, and refuted the criticism that
TBP was fortuitously providing an activation domain.
The second result involved the biochemical analysis of a
mutation in GAL11, a component of the holoenzyme
[1,3], which increased the potency of GAL4-derived
activators in vivo. This mutant, called GALl 1P for poten-
tiator [13], was shown by Ptashne and colleagues to con-
tact the GAL4-dimerization region in vitro, creating a
novel interaction that apparently mimicked the effects of
natural activators [3]. Mutations in the GAL4 dimer
region that eliminated interaction with GALl 1P also
eliminated the potentiator phenotype. The data were
interpreted as evidence that a single protein-protein
interaction between a DNA-binding protein and the
holoenzyme was sufficient to recruit it to the promoter,
where it activated a gene. Although the natural targets of
the acidic GAL4 activation domain are not known, the
chimera GAL4-VP16 interacts with components of the
mediator [14], several general factors and a TBP-associated
factor or TAF (reviewed in [15]).
One prediction of the recruitment hypothesis was that
targeting GAL11 to a promoter by a LexA-GAL11
fusion would target the holoenzyme, thereby circum-
venting the requirement for upstream activators. Indeed,
a LexA-GAL11 fusion protein resulted in high levels of
transcription in vivo from reporter templates bearing only
upstream LexA-binding sites and a TATA box [3]. The
ability of both LexA-GAL11 and LexA-TBP to bypass
activators is consistent with the idea that TBP and
GAL11 are part of the holoenzyme in the cell, a supposi-
tion further supported by the finding that TBP co-puri-
fies with the holoenzyme during early stages of its
isolation in vitro [16]. A single-step model would imply
that, in some instances, a single molecule of a potent
activator could stimulate transcription from a high-affin-
ity binding site in yeast, a prediction borne out using
GAL4 and GAL4-VP16 [17,18].
How does this scheme accommodate the phenomenon
of synergy? Natural yeast promoters invariably contain
multiple activator-binding sites that elicit greater-than-
additive transcriptional responses in vivo. One could
imagine that yeast activators are normally present in the
cell at subsaturating concentrations, and that cooperative
binding to multiple low-affinity sites is required to target
them to a promoter, where a single molecule would then
contact the holoenzyme [17]. An alternative explanation
is that some activators interact weakly with the holo-
enzyme, and that multiple interactions with different
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surfaces or components of the complex are required to
recruit it to promoter DNA.
The latter model would have a precedent in the artificial
case of cI and CAP in E. coli [12], and would agree with
a wealth of biochemical data in mammalian systems, in
which a single activator is rarely sufficient to turn on a
gene but multiple activators elicit strong synergistic
effects. These effects are often observed under site-satu-
rating conditions, which effectively eliminate the possi-
bility of cooperative DNA binding [19]. In these systems,
activators apparently stimulate transcription by affecting
different steps in the assembly of the transcription com-
plex, including the binding of TFIID and TFIIA to the
TATA box, or the binding of TFIIB to TFIID (reviewed
in [15]). Are these factors part of a mammalian holoen-
zyme in vivo? Alternatively, are distinct steps necessary to
regulate the fidelity of sophisticated higher eukaryotic
regulatory mechanisms such as combinatorial control, or
even possibly to distinguish initiation from reinitiation?
Whatever the answer to these questions, the extraordi-
nary degree of conservation between the yeast and mam-
malian general transcription systems challenges us to
strive towards a unifying view of gene activation.
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